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Corneal nerve loss as a surrogate 
marker for poor pial collaterals 
in patients with acute ischemic 
stroke
Adnan Khan1, Ajay Menon1, Naveed Akhtar2, Saadat Kamran2, Ahmad Muhammad2, 
Georgios Ponirakis1, Hoda Gad1, Ioannis N. Petropoulos1, Faisal Wadiwala2, Blessy Babu2, 
Adeeb M. Narangoli1, Pablo G. Bermejo3, Hanadi Al Hamad4, Marwan Ramadan4, 
Peter Woodruff5,6, Mark Santos2, Maher Saqqur7, Ashfaq Shuaib8 & Rayaz A. Malik1*
In patients with acute ischemic stroke, pial collaterals play a key role in limiting neurological disability 
by maintaining blood flow to ischemic penumbra. We hypothesized that patient with poor pial 
collaterals will have greater corneal nerve and endothelial cell abnormalities. In a cross-sectional 
study, 35 patients with acute ischemic stroke secondary to middle cerebral artery (MCA) occlusion 
with poor (n = 12) and moderate-good (n = 23) pial collaterals and 35 healthy controls underwent 
corneal confocal microscopy and quantification of corneal nerve and endothelial cell morphology. 
In patients with MCA stroke, corneal nerve fibre length (CNFL) (P < 0.001), corneal nerve fibre 
density (CNFD) (P = 0.025) and corneal nerve branch density (CNBD) (P = 0.002) were lower compared 
to controls. Age, BMI, cholesterol, triglycerides, HDL, LDL, systolic blood pressure, NIHSS and 
endothelial cell parameters did not differ but mRS was higher (p = 0.023) and CNFL (p = 0.026) and 
CNBD (p = 0.044) were lower in patients with poor compared to moderate-good collaterals. CNFL 
and CNBD distinguished subjects with poor from moderate-good pial collaterals with an AUC of 72% 
(95% CI 53–92%) and 71% (95% CI 53–90%), respectively. Corneal nerve loss is greater in patients with 
poor compared to moderate-good pial collaterals and may act as a surrogate marker for pial collateral 
status in patients with ischemic stroke.
Stroke is a major cause of disability and the second leading cause of  death1. Ischemic stroke typically occurs 
following occlusion of a cerebral artery due to in situ thrombosis or an embolus from the heart or neck  vessels2. 
Several studies have shown that the “leptomeningeal collateral circulation”, or “pial collateral status” determines 
the neurological outcome following acute ischemic  stroke3. Pial collaterals are anastomotic connections located 
on the pial surface of the cortex that connect distal branches of the anterior, middle and posterior cerebral arter-
ies, which permit blood flow from the territory of an unobstructed artery into the territory of an occluded  artery4. 
Indeed, patients with poor pial collaterals sustain larger infarcts, respond poorly to reperfusion, have increased 
risk for and severity of intracerebral hemorrhage and suffer increased morbidity and  mortality3,5–7, whereas those 
with good collaterals have better reperfusion, smaller infarcts and less hemorrhagic  transformation4. A method 
to help to identify the pial collateral status in stroke patients may allow risk stratification and more aggressive 
or targeted interventions to reduce neurologic disability.
There is considerable variability in the pial collateral status amongst patients with acute ischemic  stroke8,9. 
Along with genetics factors, several modifiable risk factors such as  hypertension10, metabolic syndrome, 
 hyperuricemia11,  smoking12 and  hyperglycemia13 are associated with poor collaterals. Animal studies have shown 
that “rarefaction of collaterals” is associated with multiple cardiovascular risk  factors14. MR imaging has also 
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shown that the presence of white matter hyperintensities is associated with a poor pial collateral  circulation15 
and disease severity is associated with poorer outcomes after  stroke16.
Corneal confocal microscopy (CCM) is a rapid non-invasive ophthalmic imaging technique that has been 
used to demonstrate axonal loss in patients with impaired glucose  tolerance17,  diabetes18,19, and other peripheral 
 neuropathies20. Our recent studies have also demonstrated a significant reduction in corneal  nerves21–23 and 
abnormalities in corneal endothelial cells in patients with  TIA24 and acute ischemic  stroke23. We have also shown 
that corneal nerve loss is associated with age,  HbA1c, lipids and blood  pressure
19 and the presence of white matter 
 hyperintensities25 in patients with acute ischemic stroke.
The aim of this study was to assess if corneal confocal microscopy-based quantification of corneal nerve and 
endothelial cell abnormalities could act as surrogate markers for the pial collateral status in patients with acute 
ischemic stroke.
Results
Thirty-five patients with acute MCA stroke were age-matched with thirty-five healthy controls (years) 
(51.54 ± 10.50 vs 52.82 ± 17.88, p = 0.717). The systolic blood pressure (mmHg) (144.71 ± 24.44 vs 132.31 ± 16.06, 
p = 0.014) was higher and HDL (mmol/l) 0.88 ± 0.21 vs 1.32 ± 0.37, p < 0.001) was lower in patients with stroke 
compared to controls.
Clinical, metabolic and neurological disability according to pial collateral status. Patients with 
MCA stroke were classified into those with poor (n = 12) and moderate-good (n = 23) pial collaterals. Age (years) 
(52.42 ± 8.39 vs 51.09 ± 11.60, p = 0.797), gender (M/F) (21/02 vs 12/00, p = 0.293), BMI (kg/m2) (27.88 ± 3.40 vs 
27.73 ± 4.39, p = 0.919), total cholesterol (mmol/l) (4.76 ± 1.26 vs 4.92 ± 0.97, p = 0.694), triglycerides (mmol/l) 
(1.59 ± 0.75 vs 1.68 ± 0.77, p = 0.632), LDL-cholesterol (mmol/l) (3.14 ± 1.00 vs 3.28 ± 0.89, p = 0.686), HDL-
cholesterol (mmol/l) (0.91 ± 0.29 vs 0.87 ± 0.15, p = 0.626), systolic blood pressure (mmHg) (145.00 ± 20.32 vs 
144.57 ± 26.76, p = 0.961) and  HbA1c (%) (7.29 ± 3.69 vs 6.02 ± 1.16, p = 0.294) did not differ significantly between 
patients with poor compared to moderate-good pial collaterals (Table 1).
The modified Rankin Scale (mRS) at admission (3.00 ± 1.54 vs 1.68 ± 1.25, p = 0.023) was significantly higher 
(44%) in patients with poor compared to moderate-good pial collaterals. Although not significant, the mRS at 
discharge (mRS: 2.22 ± 1.79 vs 0.83 ± 1.04, p = 0.067), and the National Institute of Health Stroke Scale (NIHSS) at 
admission (14.67 ± 6.31 vs 10.68 ± 5.96, p = 0.065) and at discharge (8.00 ± 6.32 vs 3.76 ± 4.72, p = 0.120) were 63%, 
37% and 53% higher in patients with poor compared to moderate-good pial collaterals, respectively (Table 1).
Corneal nerve and endothelial cell parameters in patients with acute ischemic stroke 
compared to controls. CNFL (mm/mm2;19.22 ± 5.78 vs 24.03 ± 5.21, p < 0.001), CNFD (no/mm2; 
30.45 ± 8.41 ± 34.62 ± 6.70, p = 0.025) and CNBD (no/mm2; 64.20 ± 35.70 vs 97.31 ± 48.21, p = 0.002) were 20%, 
12% and 34% lower in patients with MCA stroke compared to controls (Fig. 1, Table 2). There was no significant 
difference in corneal endothelial cell density (ECD) (no./mm2) (2876.61 ± 374.58 vs 2924.95 ± 229.20, p = 0.790), 
endothelial cell area (ECA) (µm2) (308.91 ± 41.19 vs 300.41 ± 21.57, p = 0.683), endothelial cell perimeter (ECP) 
(µm) (64.64 ± 4.33 vs 63.75 ± 2.60, p = 0.763), endothelial cell polymegathism (%) (49.62 ± 3.61 vs 52.38 ± 5.87, 
Table 1.  Demographic, metabolic, and clinical characteristics of healthy controls and participants with acute 
ischemic stroke with moderate-good and poor pial collaterals expressed as mean ± SD. *Statistically significant 
differences between groups.
Parameters All control (n = 35) All stroke (n = 35) P-value
Moderate-good 
collateral (n = 23)
Poor collateral 
(n = 12) P-value
Age (years) 52.82 ± 17.88 51.54 ± 10.50 0.717 51.09 ± 11.60 52.42 ± 8.39 0.797
Gender (M/F) 22/13 33/02  < 0.001* 21/02 12/00 0.293
BMI (kg/m2) 27.89 ± 5.06 27.79 ± 4.01 0.926 27.73 ± 4.39 27.88 ± 3.40 0.919
Systolic blood pressure 
(mmHg)
132.31 ± 16.06 144.71 ± 24.44 0.014* 144.57 ± 26.76 145.00 ± 20.32 0.961
HbA1c (%) 5.59 ± 0.42 6.45 ± 2.37 0.055 6.02 ± 1.16 7.29 ± 3.69 0.294
Total cholesterol 
(mmol/l)
4.95 ± 0.87 4.86 ± 1.07 0.715 4.92 ± 0.97 4.76 ± 1.26 0.694
Triglycerides (mmol/l) 1.60 ± 1.48 1.65 ± 0.75 0.887 1.68 ± 0.77 1.59 ± 0.75 0.632
LDL (mmol/l) 2.98 ± 0.72 3.23 ± 0.92 0.251 3.28 ± 0.89 3.14 ± 1.00 0.686
HDL (mmol/l) 1.32 ± 0.37 0.88 ± 0.21  < 0.001* 0.87 ± 0.15 0.91 ± 0.29 0.626
mRS at admission NA 2.15 ± 1.48 NA 1.68 ± 1.25 3.00 ± 1.54 0.023*
mRS 90 days after 
discharge
NA 1.30 ± 1.46 NA 0.83 ± 1.04 2.22 ± 1.79 0.067
NIHSS at admission NA 12.09 ± 6.30 NA 10.68 ± 5.96 14.67 ± 6.31 0.065
NIHSS 90 days after 
discharge
NA 5.23 ± 5.60 NA 3.76 ± 4.72 8.00 ± 6.32 0.120
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p = 0.112) or pleomorphism (%) (27.25 ± 4.64 vs 26.95 ± 5.10, p = 0.864) between patients with stroke compared 
to controls (Fig. 2, Table 2).
Corneal nerve and endothelial cell parameters in patients with poor compared to good pial 
collaterals. CNFL (mm/mm2) (16.26 ± 5.84 vs 20.76 ± 5.22, p = 0.026) and CNBD (no/mm2) (47.53 ± 30.04 vs 
72.89 ± 35.89, p = 0.044) were 22% and 35% lower, with no difference in CNFD (p = 0.231) between patients with 
poor compared to moderate-good collaterals, respectively (Table 2, Fig. 3). There was no significant difference 
in ECD (no./mm2) (2697.86 ± 386.66 vs 2974.11 ± 346.57, p = 0.152), ECA (µm2) (329.44 ± 44.37 vs 297.71 ± 36.6, 
p = 0.133), ECP (µm) (66.67 ± 4.68 vs 63.54 ± 3.9, p = 0.160), endothelial cell polymegathism (%) (49.00 ± 2.6 vs 
49.95 ± 4.14, p = 0.621) or pleomorphism (%) (28.28 ± 2.82 vs 26.68 ± 5.43, p = 0.515) between patients with poor 
compared to moderate-good collaterals (Fig. 2, Table 2).
Diagnostic accuracy for distinguishing patients with poor from moderate-good collater-
als. Table 3 and Fig. 4 show the diagnostic accuracy of CCM measures for identifying patients with poor 
compared to moderate-good collaterals. CNFL and CNBD distinguished subjects with poor from good collater-
als with 72% AUC (95% CI 53–92%) and 71% AUC (95% CI 53–90%), respectively. Using an abnormal cutoff 
Figure 1.  Dot plots of corneal nerve fiber parameters: (A) corneal nerve fiber length (CNFL), (B) corneal 
nerve fiber density (CNFD), (C) and corneal nerve branch density (CNBD), in controls, all stroke and stroke 
participants with poor compared to moderate-good collaterals.
Table 2.  Corneal nerve and endothelial cell measures comparing controls to patients with acute ischemic 
stroke and between patients with moderate-good and poor collaterals expressed as mean ± SD. *Statistically 
significant differences between groups tested using t-test at p < 0.05 (data in bold).
Corneal nerve 
parameters Control (n = 35) All stroke (n = 35) P-value
Moderate-good 
collateral (n = 23) Poor collateral (n = 12) P-value
Corneal nerve parameters
CNFL, mm/mm2 24.03 ± 5.21 19.22 ± 5.78  < 0.001* 20.76 ± 5.22 16.26 ± 5.84 0.026*
CNFD, no/mm2 34.62 ± 6.70 30.45 ± 8.41 0.025* 31.70 ± 6.85 28.07 ± 10.74 0.231
CNBD, no/mm2 97.31 ± 48.21 64.20 ± 35.70 0.002* 72.89 ± 35.89 47.53 ± 30.04 0.044*
Endothelial cell 
parameters Control (n = 16) All stroke (n = 17) P-value
Moderate-good 
collateral (n = 11) Poor collateral (n = 6) P-value
Corneal endothelial cell parameters
ECD, cells/mm2 2924.95 ± 229.20 2876.61 ± 374.58 0.790 2974.11 ± 346.57 2697.86 ± 386.66 0.152
ECA, µm2 300.41 ± 21.57 308.91 ± 41.19 0.683 297.71 ± 36.6 329.44 ± 44.37 0.133
ECP, µm 63.75 ± 2.60 64.64 ± 4.33 0.763 63.54 ± 3.9 66.67 ± 4.68 0.160
EC Polymegathism, % 52.38 ± 5.87 49.62 ± 3.61 0.112 49.95 ± 4.14 49.00 ± 2.6 0.621
EC Pleomorphism, % 26.95 ± 5.10 27.25 ± 4.64 0.864 26.68 ± 5.43 28.28 ± 2.82 0.515
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Figure 2.  Dot plots of corneal endothelial cell (EC) parameters: (A) endothelial cell density, (B) endothelial cell 
area, (C) endothelial cell perimeter, (D) endothelial cell polymegathism (E) and endothelial cell pleomorphism 
in patients with poor compared to moderate-good collaterals.
Figure 3.  Corneal nerve morphology in a healthy control (A), patient with moderate-good pial collaterals (B) 
and patient with poor pial collaterals (C).
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of CNFL ≤ 16 the sensitivity and specificity were 96% and 58%, respectively, and using an abnormal cutoff of 
CNBD ≤ 62 the sensitivity and specificity were 65% and 75% according to the Youden index.
Discussion
In this study, we show evidence of corneal nerve loss in patients with acute MCA stroke which agrees with our 
recent studies in patients with  TIA24,  acute21,23 and recurrent  stroke22. Moreover, we show that corneal nerve loss 
was greater and there was good diagnostic accuracy for differentiating patients with poor compared to moderate-
good pial collaterals, despite comparable blood pressure, lipids and  HbA1c. We have previously shown corneal 
endothelial cell abnormalities in patients with TIA and  stroke23, however, the current study showed no differences 
between patients with MCA stroke and controls or between patients with good compared to poor pial collaterals.
Although the pial collateral status plays a major role in determining neurological outcomes in acute ischemic 
stroke it can only be ascertained following the occurrence of large cerebral artery occlusion. White matter hyper-
intensities (WMH) predict poor stroke outcomes 90  days26–28 after thrombectomy and the presence of WMH 
was associated with greater cerebrovascular dysfunction in patients with large vessel  occlusion15, whilst those 
without WMH had more favorable outcomes in the ASPECT  score28. WMH are also associated with endothelial 
 dysfunction29 and poor pial collateral  circulation15. Indeed, many of the risk factors and comorbidities associated 
with WMHs have also been associated with poor pial collateral status. WMH increase with  age30,  hypertension31,32 
and  diabetes33,34 and may improve with antiplatelet  therapy35 and improved management of  hypertension31,32 
and  diabetes33,34. Of relevance to the current study, these same risk factors have been related to corneal nerve 
 degeneration36 and indeed improvement in blood pressure, lipids and glycemic control is associated with corneal 
nerve  regeneration37,38. Moreover, recently we showed that CCM may act as a surrogate imaging marker for the 
presence and severity of WMHs in patients with acute ischemic  stroke25.
CCM has emerged as a powerful non-invasive ophthalmic imaging endpoint to identify corneal nerve loss as a 
surrogate marker for neurodegeneration in patients with multiple  sclerosis39, Parkinson’s  disease40,  dementia41and 
patients with acute ischemic  stroke21 and recurrent  stroke22. We now show that CCM identifies greater corneal 
nerve loss in patients with poor compared to moderate/good pial collaterals. This ophthalmic imaging method 
may therefore act as a surrogate marker for poor pial collaterals and allow the identification of patients who 
require greater risk factor reduction and more urgent reperfusion after ischemic stroke. Indeed, in the present 
study patients with poor pial collaterals had a higher mRS and a previous study showed a larger infarct volume 
and higher mRS and NIHSS in patients with worse pial collateral  scores42.
Table 3.  Receiver operating characteristic (ROC) curve analysis for the diagnostic accuracy of corneal 
confocal microscopy for identifying patients with poor compared to moderate-good collaterals.
CCM parameters AUC % (95% Cl) P value Cutoff point Sensitivity (%) Specificity (%)
CNFL, mm/mm2 72 (53–92)  = 0.034  ≤ 16 96 58
CNBD, no./mm2 71 (53–90)  = 0.040  ≤ 62 65 75
Figure 4.  ROC analysis showing the area under the curve for corneal nerve fiber length and branch density for 
differentiating patients with poor from those with moderate-good pial collaterals.
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Limitations of the current study include the moderate sample size and the assessment of only patients with 
moderate disability who could undergo CCM. However, our study broadens the clinical utility of CCM in patients 
with neurodegenerative disease and patients with ischemic stroke. These data warrant larger studies utilising 
CCM in patients with or who are at risk of ischemic stroke.
Materials and methods
Thirty-five patients with middle cerebral artery occlusion and 35 age-matched healthy control participants 
attending the geriatric department at Hamad Medical Corporation were recruited from 2016 to 2018 in Doha, 
Qatar. In this cross-sectional study, exclusion criteria for participants with ischemic stroke were stroke due to a 
non-vascular disorder, or intracerebral hemorrhage, a known history of ocular trauma or surgery, high refractive 
error, and glaucoma. Healthy controls participants without known ocular or systemic co-morbidities including 
diabetes mellitus were also recruited.
Acute ischemic stroke was confirmed clinically and radiologically using American Heart Association (AHA) 
 criteria43. The pial collateral status was established using multi-modal/dynamic CTA according to the criteria of 
Tan et al.44 by an investigator who was blinded to the patient’s corneal morphology status. The ordinal collateral 
score ranges from 0 to 3: 0 = absent collateral supply to the occluded MCA territory, 1 = collateral supply fill-
ing ≤ 50% but > 0% of the occluded MCA territory, 2 = collateral supply filling > 50% but < 100% of the occluded 
MCA territory and 3 = 100% collateral supply of the occluded MCA territory. Patients with pial collateral vessels 
filling equal to or less than 50% of the occluded middle cerebral artery territory were defined as those with ‘poor 
collaterals’ whereas patients with collateral vessels filling more than 50% of the occluded middle cerebral artery 
territory were defined as those with ‘moderate- good collaterals’.
Clinical and demographic data along with blood pressure,  HbA1c and lipid profile were obtained at admission. 
The National Institutes of Health Stroke Scale (NIHSS)45 and modified Rankin Scale (mRS)46 was obtained for 
all patients at admission and at discharge from hospital. This study adhered to the tenets of the declaration of 
Helsinki and was approved by the Institutional Review Board of Weill Cornell Medicine (15-00021) and Hamad 
Medical Corporation (15304/15). Informed, written consent was obtained from all patients/guardians before 
participation in the study.
Corneal confocal microscopy. All patients underwent CCM (Heidelberg Retinal Tomograph III Ros-
tock Cornea Module; Heidelberg Engineering GmbH, Heidelberg, Germany). CCM uses a 670 nm wavelength 
helium neon diode laser, which is a class I laser and therefore does not pose any ocular safety hazard. A × 63 
objective lens with a numeric aperture of 0.9 and a working distance, relative to the applanating cap (TomoCap; 
Heidelberg Engineering GmbH) of 0.0 to 3.0 mm, is used. The size of each 2-dimensional image produced is 
384 × 384 pixels with a 15° × 15° field of view and 10 μm/pixel transverse optical resolutions. To perform the 
CCM examination, local anesthetic (0.4% benoxinate hydrochloride; Chauvin Pharmaceuticals, Chefaro, United 
Kingdom) was used to anesthetize both eyes, and Viscotears (Carbomer 980, 0.2%, Novartis, United Kingdom) 
was used as the coupling agent between the cornea and the cap. Patients were asked to fixate on an outer fixation 
light throughout the CCM scan and a CCD camera was used to correctly position the cap onto the  cornea20. The 
examination took approximately 10 min for both eyes. The examiners captured images of the central sub-basal 
nerve plexus using the section mode. On the basis of depth, contrast, focus, and position, 6 images per patient 
were  selected47.
All CCM images were manually analysed using validated, purpose-written software by an investigator blinded 
to the collateral status of the participants. Corneal nerve fiber density (CNFD: total number of major nerves/
mm2), corneal nerve branch density (CNBD: number of branches emanating from major nerve trunks/mm2), 
corneal nerve fiber length (CNFL: total length of all nerve fibers and branches mm/mm2) and inferior whorl 
length (IWL: total length of all nerve fibers in the inferior whorl area mm/mm2) were analyzed using CCMetrics 
(M. A. Dabbah, ISBE, University of Manchester, Manchester, United Kingdom)18. Corneal endothelial cell images 
were analyzed using the Corneal Endothelium Analysis System (CEAS), an automated image analysis  system48. 
Endothelial cell density (ECD, cells/mm2), endothelial cell area (ECA, µm2), endothelial cell perimeter (ECP, µm), 
endothelial cell polymegathism (%) and endothelial cell pleomorphism (%) were quantified. Polymegathism was 
defined as the standard deviation of the cell area divided by the mean cell area, while pleomorphism was defined 
as the hexagonality coefficient. Adequate corneal endothelial cells images were available in seventeen patients 
with poor (n = 6) and moderate-good (n = 11) collaterals and sixteen healthy controls.
Statistical analysis. All statistical analyses were performed using IBM SPSS Statistics software Version 25. 
Normality of the data was assessed using the Shapiro–Wilk test and by visual inspection of the histogram and 
a normal Q-Q plot. Data are expressed as mean ± standard deviation (SD). Mann Whitney test (for non-nor-
mally distributed variables) and t-test (for normally distributed variables) were performed to find the differences 
between two groups. Receiver operating characteristic (ROC) curve analysis was performed for corneal nerve 
parameters to identify patients with poor compared to moderate-good collateral status.
Ethics approval. This study adhered to the tenets of the declaration of Helsinki and was approved by the 
Institutional Review Board of Weill Cornell Medicine (15-00021) and Hamad General Hospital (15304/15).
Consent to participate. Informed, written consent was obtained from all patients/guardians before par-
ticipation in the study.
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Consent for publication. Written consent was obtained from all patients/guardians for publications.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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